[{"title": "Plus Therapeutics Approves Key Proposals at Annual Meeting", "url": "https://www.msn.com/en-us/money/topstocks/plus-therapeutics-approves-key-proposals-at-annual-meeting/ar-AA1KpoRu", "snippet": "An announcement from Plus Therapeutics ( ($PSTV) ) is now available. On August 7, 2025, Plus Therapeutics held its Annual Meeting of Stockholders", "published": "2025-08-12T21:17:20+00:00"}, {"title": "Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights", "url": "https://www.manilatimes.net/2025/08/15/tmt-newswire/globenewswire/plus-therapeutics-reports-second-quarter-financial-results-and-recent-business-highlights/2168337", "snippet": "Net income for second quarter of 2025 was $5.2 million, or $0.02 per share, compared to a net loss of $2.9 million, or $ (0.45) per share, for the same quarter the prior year; the substantial change is due to $6.5 million of pre-tax income from change in the fair value of derivative instruments", "published": "2025-08-14T20:31:00+00:00"}, {"title": "Plus Therapeutics files to sell 33M shares of common stock for holders", "url": "https://www.msn.com/en-us/money/topstocks/plus-therapeutics-files-to-sell-33m-shares-of-common-stock-for-holders/ar-AA1Kp195", "snippet": "Plus Therapeutics (NASDAQ:PSTV) filed a prospectus for the offer and sale of 33M shares of common stock by the selling stockholder.\u00a0 This prospectus is not an offer to sell these securities.\u00a0 Filing.", "published": "2025-08-12T20:53:51+00:00"}, {"title": "Plus (PSTV) Upgraded to Buy: Here's What You Should Know", "url": "https://www.nasdaq.com/articles/plus-pstv-upgraded-buy-heres-what-you-should-know", "snippet": "Plus (PSTV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.", "published": "2025-04-01T16:00:00+00:00"}]